Breast Cancer (BC)
Breast cancer (BC) is a complex and devastating disease that has a profound impact worldwide. The demand for the development of highly effective drugs and therapies to combat this condition cannot be emphasized enough. As a pioneering company specializing in rare oncology, we are fully committed to offering comprehensive services for the advancement of BC drug and therapy development.
Overview of Breast Cancer (BC)
Breast cancer, a malignancy originating from breast cells, is a prevalent tumor worldwide, constituting approximately 12.5% of newly diagnosed cancer cases annually. Although it can affect both males and females, it is more commonly found in women. The defining characteristic of breast cancer is the uncontrolled growth and division of abnormal cells within the breast tissue. These anomalous cells can invade nearby tissues and potentially spread to distant locations in the body, a process known as metastasis.
Pathogenesis of Breast Cancer (BC)
- Genetic Factors: Certain gene mutations, such as BRCA mutation, are associated with an increased risk of developing BC.
- Hormonal Factors: Hormonal imbalances, such as high estrogen levels or prolonged exposure to estrogen, can contribute to BC development.
- Family History: Having a first-degree relative (parent, sibling, or child) with BC increases the risk of developing the disease.
Fig. 1 Therapeutics for Breast Cancer. (Burguin, Anna, et al., 2021)Targets of Breast Cancer (BC) Therapy
Estrogen Receptors (ER)
ER-positive BC relies on estrogen signaling for growth and proliferation. Targeting ER with selective estrogen receptor modulators (SERMs) or estrogen receptor downregulators (ERDs) can disrupt this signaling and inhibit tumor growth.
Progesterone Receptors (PR)
PR-positive BC is also dependent on progesterone signaling. Targeting PR can be an effective strategy for hormone receptor-positive BC therapeutics.
Human Epidermal Growth Factor Receptor 2 (HER2)
HER2-positive BC is characterized by overexpression of the HER2 protein. Targeting HER2 with monoclonal antibodies or small molecule inhibitors can effectively inhibit HER2-driven tumor growth.
PI3K/AKT/mTOR Pathway
This signaling pathway plays a crucial role in BC cell survival and proliferation. Targeting key components of this pathway, such as PI3K, AKT, or mTOR, can be an effective strategy for BC.
Cell Cycle Regulators
Disruption of cell cycle regulation is a hallmark of cancer, including BC. Targeting cell cycle checkpoints, such as cyclin-dependent kinases (CDKs), can prevent cancer cell division and induce cell death.
Therapies of Breast Cancer (BC)
| Targeted Therapy | Drug Name | Population | Trial Arms |
| mTOR inhibitors | Everolimus | TNBC Advanced BC Prior systemic therapeutics |
Everolimus + caroboplatin vs. carboplatin alone |
| Akt inhibitors | Ipatasertib | ER+/HER2- Post-menopausal Prior CDK4/6 inhibitors and AIs |
Ipatasertib + fulvestrant verus placebo + fulvestrant |
| CDK4/6 inhibitors | Ribociclib | HR+/HER2- PIK3CA mutated Postmenopausal Locally advanced or MBC No prior systemic therapeutics |
Ribociclib + letrozole |
| Abemaciclib | HR+/HER2- Post-menopausal Stage I to III Prior endocrine therapeutics |
Abemaciclib + fulvestrant | |
| Palbociclib | HR+/HER2- Post-menopausal Locally advanced or MBC Prior chemotherapy |
Palbociclib + fulvestrant | |
| Trastuzumab-duocarmycin | HER2+ Locally advanced or MBC Prior anti-HER2 therapeutics |
Trastuzumab-duocarmycin vs. standard Prior systemic therapeutics | |
| RC48 | HER2+ Locally advanced or MBC Prior systemic therapeutics |
RC48 vs. lapatinib + capecitabine |
Our Services
With a research team with extensive expertise in breast cancer research as well as an advanced technology platform, our company is dedicated to advancing BC diagnostics and therapy development through our comprehensive services.
Types of Breast Cancer (BC)
Therapy Development Platforms
Our expertise in developing BC animal models allows us to conduct preclinical studies to assess the safety, efficacy, and pharmacokinetics of novel drugs and therapies. These studies provide valuable insights into the potential benefits and limitations of the therapeutics approach.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Burguin, Anna, Caroline Diorio, and Francine Durocher. "Breast cancer treatments: updates and new challenges." Journal of personalized medicine 11.8 (2021): 808.
- Tong, Christy WS, et al. "Recent advances in the treatment of breast cancer." Frontiers in oncology 8 (2018): 227.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.